Product logins

Find logins to all Clarivate products below.


Gout – Current Treatment – Treatment Algorithms: Claims Data Analysis – Gout (US)

Gout is a form of inflammatory arthritis caused by sustained hyperuricemia, or elevated serum uric acid (sUA) levels. This condition manifests through sudden and intense gout flares, causing significant discomfort. The therapeutic approach for acute flares differs from chronic gout management, and it is not the focus of this analysis. Chronic treatment aims to prevent recurrent gout attacks and limit joint damage by lowering sUA levels. Xanthine oxidase inhibitors (XOIs), especially the widely prescribed generic allopurinol, form the cornerstone of chronic gout treatment. For later lines of therapy, pegloticase (Krystexxa), a highly efficacious biological agent, is utilized. This report provides valuable insights into the use of these treatments in patients with newly diagnosed or recently treated chronic gout.

Questions answered

  • What patient shares do key therapies and brands garner by line of therapy in newly diagnosed chronic gout patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed chronic gout patients?
  • How has pegloticase been integrated into the treatment algorithm, and what is its source of business?
  • What percentage of chronic gout patients receive drug therapy within 365 of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within 365 of diagnosis?
  • What percentage of chronic gout patients are treated with monotherapy vs. combination therapy? What are the most used combinations?
  • What are the product-level compliance and persistency rates among drug-treated patients?

Product description

Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data, enabling you to:

  • Understand patient flow between lines of therapy.
  • Evaluate your brand share against competitors.
  • Accurately assess your source of business.
  • Quantify opportunities at different stages of the treatment algorithm.

Product enhancement

Treatment Algorithms: Claims Data Analysis leverages Clarivate’s proprietary Real-World Data, which brings larger patient samples, broader payer coverage, and faster availability for more robust and timely analyses. Additionally, we include new patient demographic analyses: age, gender, ethnicity, and region.

Related Market Assessment Reports

Report
Ovarian Cancer – Landscape & Forecast – Disease Landscape & Forecast (G7)
The treatment landscape for ovarian cancer has been revolutionized by the angiogenesis inhibitor bevacizumab and the PARP inhibitors olaparib (Lynparza; AstraZeneca / Merck & Co.), niraparib (…
Report
Myelodysplastic Syndromes – Landscape & Forecast – Niche & Rare Disease Landscape & Forecast
Myelodysplastic syndromes (MDS) are a heterogeneous group of hematopoietic stem cell disorders that result in cytopenia with the risk of progression to acute myeloid leukemia (AML). The FDA’s and…
Report
Ulcerative Colitis – Unmet Need – Unmet Need – Moderate to Severe Ulcerative Colitis (US/EU)
The treatment landscape for ulcerative colitis (UC) is rapidly evolving. TNF-alpha inhibitors (Johnson & Johnson Innovative Medicine’s Remicade, AbbVie’s Humira), a CAM inhibitor (Takeda’s…
Report
Hepatitis B Virus – Geographic Focus: China – China In-Depth – Hepatitis B Virus
HBV is a major public health burden in China, with chronically infected individuals at a significantly increased risk of developing hepatic cirrhosis and hepatocellular carcinoma. Current treatment…
Report
Vitiligo – Current Treatment – Treatment Algorithms: Claims Data Analysis – Vitiligo (US)
Vitiligo is a chronic skin depigmentation disorder characterized by the destruction or functional loss of melanocytes. Given its visible manifestations, the disease is associated with a substantial…